Skip to main content
. 2012 Jun 18;7(6):e39167. doi: 10.1371/journal.pone.0039167

Figure 1. Over-expression of miR-337-3p sensitizes NCI-H1155 cells to paclitaxel.

Figure 1

(A) Dose-dependent effect of paclitaxel on cell viability in the presence or absence of miR-337-3p mimic. Cell viability was measured using the MTS assay. (*, p<0.05; **, p<0.01; ***, p<0.001; ns, not significant) (B) Cell viability as a function of oligo concentration in the presence or absence of paclitaxel. Cell viability was measured using the ATP concentration assay. (C) Effect of miR-337-3p knockdown with miR-337-3p inhibitor (50 nM) on paclitaxel sensitivity in H1155 cells. Shown is the relative cell viability in the presence of 16 nM paclitaxel normalized to control oligos. (****, p<0.0001) (D) Cell cycle analysis as a function of miR-337-3p overexpression and paclitaxel treatment. The fraction of cells in G1, S and G2 phases was estimated using the Watson pragmatic model, with the ratio of G2 to G1 fractions for paclitaxel treated cells normalized to that observed for control conditions (R = [G2/G1]paclitaxel/[G2/G1]carrier).